source
- AstraZeneca and Amgen’s Tezspire eyes Dupixent’s EoE stronghold after late-stage trial winAnalysts note that AstraZeneca and Amgen have secured a late‑stage trial win for Tezspire, positioning the drug as a possible challenger to Dupixent in eosinophilic esophagitis (EoE). Dupixent re…
- Multispecific antibodies push CDMOs to redesign development platformsManufacturers are moving beyond traditional monoclonal-antibody platforms as multispecific therapeutics gain traction. The new design model relies on molecular engineering, advanced analytics, and…